Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones  by Suphaphiphat, Pirada et al.
A
s
P
P
a
b
a
A
R
R
A
A
K
S
A
H
1
g
f
p
a
c
a
d
R
h
0Vaccine 34 (2016) 3641–3648
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
ntigenic  characterization  of  inﬂuenza  viruses  produced  using
ynthetic  DNA  and  novel  backbones
irada  Suphaphiphata,∗,  Lynne  Whittakerb,  Ivna  De  Souzaa, Rodney  S.  Danielsb,
hilip  R.  Dormitzera,1, John  W.  McCauleyb,  Ethan  C.  Settembrea
Seqirus (previously Novartis Inﬂuenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA
Crick Worldwide Inﬂuenza Centre, The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London NW7  1AA, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 5 February 2016
eceived in revised form 27 April 2016
ccepted 12 May  2016
vailable online 21 May  2016
eywords:
ynthetic inﬂuenza virus
ntigenicity
emagglutination inhibition
a  b  s  t  r  a  c  t
The  global  system  for  manufacturing  seasonal  inﬂuenza  vaccines  has  been  developed  to respond  to  the
natural  evolution  of inﬂuenza  viruses,  but  the  problem  of antigenic  mismatch  continues  to  be  a  challenge
in certain  years.  In  some  years,  mismatches  arise  naturally  due  to  the  antigenic  drift  of  circulating  viruses
after vaccine  strain  selection  has  already  been  made.  In  other  years,  antigenic  differences  between  the
vaccine  virus  and  circulating  viruses  are  introduced  as  part of  the  current  system,  which  relies  on the  use
of  egg-adapted  isolates  as a starting  material  for  candidate  vaccine  viruses  (CVVs).  Improving  the  current
process  for  making  vaccine  viruses  can  provide  great  value.  We  have  previously  established  a  synthetic
approach  for  rapidly  generating  inﬂuenza  viruses  in a vaccine-approved  Madin  Darby  canine  kidney
(MDCK)  cell  line  using  novel,  high-growth  backbones  that increase  virus rescue  efﬁciency  and  antigen
yield.  This  technology  also  has the potential  to  produce  viruses  that  maintain  antigenic  similarity  to the
intended  reference  viruses,  depending  on the  hemagglutinin  (HA)  and  neuraminidase  (NA)  sequences
used  for gene  synthesis.  To  demonstrate  this  utility,  we  generated  a panel  of  synthetic  viruses  using
HA  and  NA  sequences  from  recent  isolates  and  showed  by  hemagglutination  inhibition  (HI)  tests  that
all  synthetic  viruses  were  antigenically-like  their  conventional  egg-  or cell-propagated  reference  strains
and  there  was  no  impact  of the novel  backbones  on antigenicity.  This  synthetic  approach  can  be  used  for
the  efﬁcient  production  of CVVs  that  may  be more  representative  of  circulating  viruses  and  may  be used
for  both  egg-  and  cell-based  vaccine  manufacturing  platforms.  When  combined  with  mammalian  cell
culture  technology  for antigen  production,  synthetic  viruses  generated  using  HA  and  NA  sequences  from
a  non-egg-adapted  prototype  can  help  to reduce  the  potential  impact  of antigenic  differences  between
vaccine  virus  and  circulating  viruses  on  vaccine  effectiveness.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Inﬂuenza viruses have a high mutation rate in their RNA
enomes and exist as complex quasi-species [1,2], a property that
acilitates their natural drift and continuously challenges vaccine
roduction. Inﬂuenza strains that circulate in humans frequently
cquire antigenically important mutations to escape immunologi-
al pressure, giving rise to new variants that can become dominant
nd cause seasonal re-infections [2,3]. These antigenic changes
ictate that the inﬂuenza vaccine be reviewed bi-annually and
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
updated almost as often. Vaccination is the most effective strategy
to protect against seasonal inﬂuenza; however, vaccine perfor-
mance varies from year to year, with decreased effectiveness
potentially associated with differences between the antigens in the
vaccine and those of circulating strains [4–6].
Currently, mammalian cells, particularly MDCK cells, are a
preferred substrate for inﬂuenza virus isolation for surveillance
activities due to their high sensitivity to infection [7]. However,
only inﬂuenza viruses that can be re-isolated and propagated exclu-
sively in embryonated hen’s eggs are recommended as CVVs for
both mammalian cell-based and egg-based vaccine manufactur-
ing platforms. This standard practice perpetuates the likelihood
of producing a vaccine that differs antigenically from circulating
viruses.
The variability of virus isolation rates in eggs, particularly for
recent H3N2 strains [8], can limit the number of suitable CVVs
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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vailable in some years. This limitation could lead to a problematic
ituation as in 2004, when no well-matched H3N2 strain could be
solated in eggs in time to produce a seasonal vaccine, resulting in
ubstantial antigenic difference between the vaccine and the H3N2
iruses in circulation at that time and an associated reduction in
accine effectiveness [5,9]. Furthermore, human-derived inﬂuenza
iruses propagated in eggs undergo selective pressure and can
cquire HA mutations that alter their binding speciﬁcity from the
-2,6-linked sialic acids that predominate in the upper human
espiratory epithelium [10] to the -2,3-linked sialic acids that pre-
ominate in the egg allantoic cavity [11,12]. Although not all egg
daptation changes in the HA molecule translate to a change in anti-
enicity, in recent years, the recommended H3N2 and B-Victoria
ineage CVVs have exhibited signiﬁcantly reduced antigenic sim-
larity to circulating strains due to a few egg-adaptive mutations
4,13,14].
Although evolutionary drift in circulating viruses cannot be con-
rolled, changes in the antigenic properties introduced as part of
urrent egg-based inﬂuenza vaccine production systems can be
liminated. It is known that inﬂuenza viruses propagated in mam-
alian cells often remain genetically and antigenically similar to
he virus present in clinical material [15–17]. Thus, the use of
iruses isolated in mammalian cell lines qualiﬁed for vaccine pro-
uction can help maintain antigenic similarity of vaccine strains to
irculating viruses [17].
We have developed an efﬁcient synthetic approach for generat-
ng high-yielding inﬂuenza viruses exclusively in vaccine-qualiﬁed
DCK cells [18]. These viruses are produced by reverse genetics
rom synthetically-derived nucleic acids based on reported HA and
A sequences and combined with optimized backbone gene seg-
ents [18]. These high-growth backbones can increase virus rescue
fﬁciency and HA yields [18], and are not expected to impact anti-
enicity. To demonstrate the ability of this synthetic approach to
rovide viruses that maintain genetic and antigenic similarity to the
ntended reference strains, we have performed a study in which
he antigenicity of a panel of synthetic viruses covering seasonal
/H1N1, A/H3N2, and B strains was compared to their respective
gg- or mammalian cell-grown reference counterparts. The H3N2
ubtype was prioritized in this study because H3N2 CVVs have
ailed to correspond antigenically to circulating strains for the past
everal years and continue to present a challenge.
. Materials and methods
.1. Cells and viruses
MDCK 33016PF cells were maintained as previously described
18]. Wild-type inﬂuenza viruses were isolated from clinical sam-
les by World Health Organization (WHO) National Inﬂuenza
enters. Egg-based reassortant viruses were generated at New York
edical College, USA, the National Institute for Biological Standards
nd Control (NIBSC), UK, or CSL, Australia. All viruses were from
tocks held at the Crick Institute, Mill Hill laboratory, UK.
.2. Synthetic DNA
HA and NA segments were assembled as previously described
18], or with the following modiﬁcations. Overlapping oligonu-
leotides were assembled using primers BMP  13 and BMP  14
18]. PCR products were denatured and re-annealed to form
ismatched duplex DNA, followed by incubation with Sur-
eyor nuclease (Transgenomic, Inc.) and Exonuclease III (NEB).
rror-corrected DNA was ampliﬁed using nested primers
MP  27 (TTGGGTAACGCCAGGGTTTTCC) and BMP  34 (TTCA-
ACAGGAAACAGCTATGACCATGATTA), and puriﬁed by ethanole 34 (2016) 3641–3648
precipitation. Final products were linear gene segments ﬂanked
by upstream and downstream regulatory control elements.
2.3. Reverse genetics
Synthetic viruses were generated as previously described [18].
Brieﬂy, synthetic HA and NA gene cassettes and plasmids carrying
the six backbone genes (PB2, PB1, PA, NP, M,  NS) and the plasmid
TMPRSS2 (encoding a serine protease [19]) were co-transfected
into MDCK cells. Clariﬁed culture medium was harvested at least
72 h post-transfection, and viruses titered by a focus-formation
assay [18]. Viruses were passaged up to 3 times in MDCK cells.
2.4. Virus sequencing
Viral RNA was  extracted using the QIAamp Viral RNA Mini
Kit (Qiagen), and cDNA generated using Monsterscript reverse
transcriptase (Epicentre). HA and NA genes were ampliﬁed using
Platinum PCR SuperMix High Fidelity DNA polymerase (Life Tech-
nologies), and sequences analyzed by Sanger DNA sequencing
(Genewiz, Cambridge, MA).
2.5. HI assays
Hemagglutination and HI assays were performed according to
standard WHO  methods [20]. Four HA units (HAU) of H3N2 strains
were tested using 1% suspensions of guinea pig red blood cells
and 20 nM oseltamivir carboxylate. HA titers were determined in
the presence of the drug. Eight HAU of H1N1 and four HAU of B
viruses were tested using 0.75% suspensions of turkey red blood
cells without oseltamivir. HI titers were reciprocals of the high-
est dilutions of sera that inhibited hemagglutination. Post-infection
ferret antisera against various reference viruses were treated with
receptor-destroying enzyme from Vibrio cholera (Cosmos Biomed-
ical, UK).
2.6. Ferret inoculation
Post-infection antisera were produced in ferrets (Mustela puto-
rius furo) following intranasal instillation of diluted virus under
light sedation, and sera were collected under terminal anaesthe-
sia at the Crick Institute Mill Hill laboratory under UK  Home Ofﬁce
project license PPL/80/2541 or were made by NIBSC, UK, under
UK Home Ofﬁce project license PIL/80/2530. Other antisera were
from the WHO  CC at the Centers for Disease Prevention and Con-
trol, Atlanta, GA, St Jude’s Children’s Research Hospital, Memphis,
TN, and the Peter Doherty Institute for Infection & Immunity, Mel-
bourne, Australia.
3. Results
3.1. Generation of synthetic viruses
Synthetic and reverse genetic technologies enable the selec-
tion of genomes to generate a new vaccine virus, based on known
virus sequences. Three optimized backbones (PR8x, #19, and #21)
derived from low pathogenicity strains [18] were used to make
inﬂuenza A viruses. The PR8x backbone contains six internal
genome segments from an MDCK-adapted A/Puerto Rico/8/1934
(H1N1) strain. The #19 backbone contains PB2, PB1, and NP
from an MDCK-adapted A/Hessen/105/2007 (H1N1) strain and
the remaining segments from PR8x. The #21 backbone contains
an A/California/07/2009 (H1N1) PB1 and the remaining segments
from PR8x. Inﬂuenza B viruses were made using all six back-
bone segments from B/Brisbane/60/2008. Rescued viruses were
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assaged up to three times in MDCK cells exclusively. Viruses gen-
rated for antigenicity testing covered seasonal inﬂuenza strains
A/H1N1, A/H3N2, and B-Victoria lineage), including four egg- and
ammalian cell-derived antigen pairs (Table S1). The HA and NA
enes of all viruses were conﬁrmed to have 100% genetic identity
o the coding sequences used for synthesis (Table S2).
.2. Antigenic characterization of synthetic viruses
We  ﬁrst demonstrated that this MDCK cell-based technology
ould generate viruses that were antigenically similar to conven-
ional egg-adapted CVVs, even though the synthetic viruses were
ever passaged in eggs. Synthetic viruses were made using HA
nd NA sequences from ﬁve egg-adapted, high-growth, reassor-
ant CVVs (NIB-74, X-187, IVR-165, X-175, or IVR-164), and virus
ntigenicity was tested by a one-way HI assay using ferret anti-
era raised against the egg-adapted CVVs or the corresponding
gg-adapted wild-type isolates (Table 1). For all ﬁve strains tested,
ntisera raised against the CVVs recognized the corresponding syn-
hetic viruses at titers ≤2-fold different from the homologous virus
iters, regardless of the backbone used. All the synthetic viruses also
eacted similarly in HI assays with ferret antiserum raised against
he egg-adapted wild-type strains, with titers ≤4-fold different
rom the homologous virus titers.
Because we aim to generate CVVs that are antigenically iden-
ical to any newly isolated wild-type strain by direct rescue on
igh-growth backbones, we extended our analysis to use HA and
A sequences from H3N2 wild-type isolates, rather than high-
rowth reassortants. Synthetic viruses were made using HA and
A sequences from two mammalian cell-grown, wild-type iso-
ates, A/Victoria/210/2009 and A/South Australia/3/2011, and from
wo egg-adapted strains, A/Texas/50/2012 and A/Berlin/93/2011
Table 2). After one passage in MDCK cells, antigenic characteriza-
ion was performed by HI tests using ferret antisera raised against
he cell- or egg-propagated wild-type strains. Viruses made with
he different backbones reacted similarly to a given antiserum, and
I titers obtained from all the tested viruses were within 4-fold of
he homologous virus titer.
.3. Synthetic viruses can improve antigenic match to strains that
ause human disease
Synthetic viruses can be made using HA and NA sequences
rom either egg- or mammalian cell-grown isolates, but the abil-
ty to genetically match a mammalian cell-grown virus would be
xpected to improve antigenic similarity to strains circulating in
he human population. It has been documented that egg-selected
hanges in HA for the recent H3N2 and B-Victoria lineage CVVs
sed in seasonal vaccines have been associated with reduced vac-
ine effectiveness [4,13]. Therefore, we used synthetic technology
o assess differences in antigenicity between mammalian cell-
nd egg-derived paired antigens for three recent H3N2 strains
nd one B-Victoria lineage strain. In the northern hemisphere,
/Victoria/210/2009 was  the H3N2 component for the 2010–2011
nd 2011–2012 vaccines; A/Victoria/361/2011-like was  the H3N2
omponent for the 2012–2013 and 2013–2014 vaccines; and
/Switzerland/9715293/2013 was the H3N2 recommendation for
he 2015–2016 vaccine. B/Brisbane/60/2008 was the B strain com-
onent for the 2009–2010, 2010–2011, and 2011–2012 trivalent
accines, and has been the B-Victoria component for quadrivalent
accines since 2012–2013. The HA sequences of all mammalian
ell- and egg-derived antigen pairs differed by 1-3 amino acids
Table S3). Notably, all the egg-derived H3 antigens contained a
186V mutation that has been shown to improve virus growth
n eggs but alter antigenicity relative to an MDCK cell-propagated
irus [21]. The egg-derived B/Brisbane/60/2008 HA loses a potentiale 34 (2016) 3641–3648 3643
glycosylation site near the receptor binding site. Loss of this glycan
upon egg adaptation has also been shown to affect antigenicity [13].
Prior to antigenic characterization, all viruses were assessed for
relative growth in MDCK cells to conﬁrm that they could be prop-
agated and potentially used as CVVs (Fig. S1), although infection
conditions were not optimized in the study to ensure maximum
virus yields.
Synthetic viruses made from either mammalian cell- or egg-
derived HA and NA sequences were compared by HI assay to their
synthetic counterpart and to conventional reference strains using
antisera raised against mammalian cell- and egg-grown reference
viruses. As shown in Tables 3 and 4, in most instances we observed
differences in reactivity between the cell- and egg-derived antigens
when analyzed with ferret antisera raised against the egg-grown
viruses, but not when analyzed with antisera raised against the
mammalian cell-grown viruses. In particular, ferret antisera raised
against the egg-grown vaccine viruses generally recognized syn-
thetic test viruses containing the egg-adapted HA sequence at a titer
within 2-fold of the homologous titers, but reacted less well in HI
assays (>4-fold decrease) to viruses expressing the corresponding
mammalian cell-derived antigens. This experimental design mod-
els the current human immunization situation, in which an immune
response against an egg-derived vaccine antigen is intended to pro-
tect against circulating strains that lack egg adaptations. However,
ferret antisera raised against the cell-grown isolates recognized
viruses expressing either the cell- or egg-derived antigens. Most
viruses reacted to a given antiserum raised against mammalian cell
grown viruses within ≤4-fold of the corresponding homologous
titer, with the exception of the antiserum that was  raised against
the cell-grown A/Victoria/361/2011, which produced a low homol-
ogous titer of 320 but reacted much better (>4-fold increase) to
viruses expressing the egg-adapted antigens (Table 3B). This sur-
prising ﬁnding might be attributed to differences in receptor avidity
between egg-adapted and cell-grown viruses, which could affect
the dynamics of the HI assay. Since recent cell-grown H3N2 viruses
appear to have a lower avidity for the sialic acid receptor, more
cell-grown A/Victoria/361/2011 virus might have been used in the
HI assay to obtain 4 HA units compared to the egg-adapted viruses,
therefore requiring more antibody to inhibit binding to red blood
cells.
The discernable antigenic difference observed between egg-
and mammalian cell-grown A/Switzerland/9715293/2013 refer-
ence viruses by one-way HI testing (Table 5) prompted us to
select this NH 2015-16 vaccine strain for additional two-way anti-
genic characterization. Ferret antisera raised against two synthetic
viruses expressing either the mammalian cell- or egg-derived anti-
gen were tested with conventional reference strains and with
synthetic viruses made on different backbones (Table 5). The two-
way HI data conﬁrmed that the synthetic viruses were antigenically
similar to their corresponding reference strains, with HI titer differ-
ences within 2-fold. Ferret antisera raised against viruses with one
backbone also effectively recognized viruses rescued on a different
backbone. Interestingly, the cell-derived synthetic and wild-type
antigens reacted better to antiserum raised to the synthetic virus
expressing egg-adapted HA (RG-PS-2404) than to antiserum raised
to the egg-adapted reference virus (≤2-fold versus 4 to 8-fold
lower than the homologous titers, respectively). It is plausible
that high growth backbones affect the amount of HA incorpora-
tion into virions, which could affect their avidity for red blood
cells and/or the amount of antibodies elicited by ferret infec-
tion with such viruses. Both of these factors could impact the
dynamics of the HI assay and are under investigation. Overall, we
have demonstrated the ability of synthetic technology to gener-
ate viruses that are more antigenically similar to the mammalian
cell-grown prototype compared to current egg-adapted vaccine
viruses.
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Table 1
HI comparison of egg-propagated non-synthetic viruses and MDCK cell-propagated synthetic viruses with HA and NA sequences derived from egg-adapted candidate vaccine viruses.
Origina Virusb Genetic
group
Passage
history
Hemagglutination inhibition titer
Ferret antisera raised to egg-propagated virusesc
NIB-74 A/CC/16 IVR-165 A/Vic/361 X-187 A/Vic/210 X-175 C A/Urug/716 IVR-164 A/Bris/299
NIBSC
F66/10
F30/10 NIB F11/12 F06/12 CDC 2010-098/
10/101
F10/11 F1082/08 F26/08 NIB F10/12 NIBSC
F12/12
CVV NIB-74 A(H1N1) Egg (E1/E3) 20480 20480
WT  A/Christchurch/16/2010 Egg (E5/E1) 20480 20480
S RG-PS-1259 (NIB-74) PR8x Cell (MDCK2) 20480 10240
S  RG-PS-1260 (NIB-74) #19 Cell (MDCK2) 20480 20480
S  RG-PS-1261 (NIB-74) #21 Cell (MDCK2) 20480 20480
CVV  IVR-165 A(H3N2) Egg (E3/D6/E1) 1280 2560
WT  A/Victoria/361/2011 Clade 3C.1 Egg (E3/E2) 640 1280
S RG-PS-1291 (IVR-165) PR8x Cell (MDCK3) 1280 1280
S  RG-PS-1242 (IVR-165) #19 Cell (MDCK3) 2560 2560
S  RG-PS-1252 (IVR-165) #21 Cell (MDCK3) 1280 2560
CVV  X-187 A(H3N2) Egg (Ex/E2/E1) 5120 2560
WT  A/Victoria/210/2009 Egg (E2/E2) 5120 2560
S RG-PS-1274 (X-187) PR8x Cell (MDCK2) 2560 1280
S  RG-PS-1266 (X-187) #19 Cell (MDCK2) 5120 640
S  RG-PS-1267 (X-187) #21 Cell (MDCK2) 2560 1280
CVV  X-175C A(H3N2) Egg (Ex/E1/E1) 2560 1280
WT  A/Uruguay/716/2007 Egg (SPCFK1/E5) 5120 2560
S RG-PS-2385 (X-175C) PR8x Cell (MDCK1) 2560 640
S  RG-ID-733 (X-175C) #19 Cell (MDCK2) 2560 1280
S  RG-PS-2358 (X-175C) #20 Cell (MDCK1) 2560 1280
CVV  IVR-164 A(H3N2) Egg (E5/C8/E1) 5120 2560
WT  A/Brisbane/299/2011 Clade 6 Egg (E5/E2) 5120 5120
S RG-PS-1472 (IVR-164) PR8x Cell (MDCK1) 5120 5120
S  RG-PS-1468 (IVR-164) #19 Cell (MDCK1) 5120 5120
S  RG-PS-1469 (IVR-164) #21 Cell (MDCK1) 5120 5120
a S, synthetic virus; CVV, egg-adapted high growth reassortant strain; WT,  egg-propagated wild-type isolate,
b,c NIB-74, IVR-165, X-187, X-175 C, and IVR-164 are the egg-adapted high growth reassortant strains of A/Christchurch/16/2010 (abbreviated as A/CC/16), A/Victoria/361/2011 (abbreviated as A/Vic/361), A/Victoria/210/2009
(abbreviated as A/Vic/210), A/Uruguay/716/2007 (abbreviated as A/Urug/716), and A/Brisbane/299/2011 (abbreviated as A/Bris/299), respectively.
Homologous titers are indicated in bold and underlined.
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Table 2
HI characterization of synthetic viruses with HA and NA sequences derived from egg- or mammalian-propagated wild-type viruses.
Origina Virusesb Genetic group Passage history Hemagglutination inhibition titer
Ferret antisera raised to wild-type isolatesc
A/Texas/50/12
egg
A/Berlin/
93/11 egg
A/South Australia/
3/11 cell
A/Victoria/
210/09 cell
F42/13 F10/12 AUG F20/08 T/C St Judes
F712/14
WT A/Texas/50/2012-egg A(H3N2) Egg (E5/E2) 2560
S RG-PS-1958 (A/Texas/50/2012-egg) PR8x clade 3C.1 Cell (MDCK1) 2560
S  RG-PS-1959 (A/Texas/50/2012-egg) #19 Cell (MDCK1) 2560
S  RG-PS-2334 (A/Texas/50/2012-egg) #21 Cell (MDCK1) 1280
WT  A/Berlin/93/2011-egg A(H3N2) Egg (NVD3/E3) 2560 640
S  RG-PS-1425 (A/Berlin/93/2011-egg) PR8x clade 3C Cell (MDCK1) 10240 2560
S  RG-PS-1286 (A/Berlin/93/2011-egg) #19 Cell (MDCK1) 5120 640
S  RG-PS-1287 (A/Berlin/93/2011-egg) #21 Cell (MDCK1) 10240 2560
WT  A/South Australia/3/2011-cell A(H3N2) Cell MDCK2/SIAT2 640 2560
S RG-PS-1322 (A/South Australia/3/2011-cell) PR8x clade 3C Cell (MDCK1) 1280 5120
S  RG-PS-1323 (A/South Australia/3/2011-cell) #19 Cell (MDCK1) 640 2560
S  RG-PS-1327 (A/South Australia/3/2011-cell) #21 Cell (MDCK1) 2560 5120
WT  A/Victoria/210/2009-cell A(H3N2) Cell (MDCK2/SIAT5) 2560
S RG-PS-2378 (A/Victoria/210/2009-cell) PR8x Cell (MDCK1) 2560
S  RG-KD-038 (A/Victoria/210/2009-cell) #19 Cell (MDCK1) 5120
S  RG-PS-2381 (A/Victoria/210/2009-cell) #21 Cell (MDCK1) 5120
a S, synthetic virus; WT,  wild-type isolate.
b,c “Egg” or “cell” refers to the passage history of the wild-type viruses or the passage history of the reference viruses that provided the HA and NA sequences to make the synthetic viruses. In cases of mixed passage history, any
passage  in eggs is sufﬁcient to trigger an “egg” designation.
Homologous titers are indicated in bold and underlined.
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Table  3
HI titers showing antigenic mismatch between viruses with egg- and mammalian cell-derived H3N2 antigens.
(A) A/Victoria/210/2009 (H3N2)
Antigen sourcea Passage history Post-infection ferret antisera
X-187
(A/Vic/210/09)-egg
A/Vic/210/
09-egg
A/Vic/210/
09-cell
CDC 2010-098/
10/101 pool
F10/11 T/C St Judes
F712/14
Reference viruses
X-187 (A/Victoria/210/2009)-egg Egg Egg (Ex/E2/E1) 5120 2560 2560
A/Victoria/210/2009-egg Egg Egg (E2/E2) 5120 2560 2560
A/Victoria/210/2009-cell Cell Cell (MDCK1/SIAT2) 640 320 2560
Synthetic test viruses
RG-PS-1274 (X-187 A/Victoria/210/2009-egg) PR8x Egg Cell (MDCK2) 2560 1280 640
RG-PS-1266 (X-187 A/Victoria/210/2009-egg) #19 Egg Cell (MDCK2) 5120 640 1280
RG-PS-1267 (X-187 A/Victoria/210/2009-egg) #21 Egg Cell (MDCK2) 2560 1280 1280
RG-PS-2378 (A/Victoria/210/2009-cell) PR8x Cell Cell (MDCK1) 1280 640 2560
RG-KD-038 (A/Victoria/210/2009-cell) #19 Cell Cell (MDCK1) 2560 640 5120
RG-PS-2381 (A/Victoria/210/2009-cell) #21 Cell Cell (MDCK1) 2560 1280 5120
(B)  A/Victoria/361/2011 (H3N2)
Antigen
sourcea
Passage history Post-infection ferret antisera
IVR-165 (A/Vic/361/11)-egg A/Vic/361/11-egg A/Vic/361/11-cell
NIB  F11/12 F06/12 F09/12
Reference viruses
IVR-165 (A/Victoria/361/2011)-egg Egg Egg (E3/D6/E1) 1280 1280 2560
A/Victoria/361/2011-egg Egg Egg (E3/E2) 640 2560 5120
A/Victoria/361/2011-cell Cell Cell (MDCK2/SIAT5) 80 320 320
Synthetic test viruses
RG-PS-1291 (IVR-165 A/Victoria/361/2011-egg) PR8x Egg Cell (MDCK3) 1280 1280 2560
RG-PS-1242 (IVR-165 A/Victoria/361/2011-egg) #19 Egg Cell (MDCK3) 2560 2560 2560
RG-PS-1252 (IVR-165 A/Victoria/361/2011-egg) #21 Egg Cell (MDCK3) 1280 2560 2560
RG-PS-1247 (A/Victoria/361/2011-cell) PR8x Cell Cell (MDCK3) 160 1280 1280
a “Egg” or “cell” refers to the passage history of the reference viruses or the passage history of the viruses that provided the HA and NA sequences to make the synthetic
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Hiruses.
omologous titers are indicated in bold and underlined.
. Discussion
Reports of antigenic differences between recommended CVVs
nd circulating viruses in recent years, particularly for H3N2 strains
4–6,13,14], has heightened public awareness and concern over
he effectiveness of seasonal inﬂuenza vaccines. This concern high-
ights the need for an improved CVV generation system that is
ot reliant on legacy, egg-based technology. Antigenic differences
ay  result from antigenic drift in circulating viruses, egg-adaptive
utations, or both. Between 2010 and 2014, HA mutations in thegg-adapted H3N2 vaccine strains resulted in antigenic changes
hat were associated with low vaccine effectiveness [4,13]. In
014–2015, the drifted A/Texas/50/2012 (H3N2) vaccine strain was
ntigenically distinct from dominant circulating strains [6,14]. Fur-
able 4
I titers showing antigenic mismatch between viruses with egg- and mammalian cell-de
Antigen sourcea Passage 
Reference viruses
B/Brisbane/60/2008-egg Egg Egg (E4/E
B/Brisbane/60/2008-cell Cell Cell (MD
Synthetic test viruses
RG-ID-1279 (B/Brisbane/60/2008-egg) Egg Cell (MD
RG-PS-1376 (B/Brisbane/60/2008-cell) Cell Cell (MD
a “Egg” or “cell” refers to the passage history of the reference viruses or the passage hi
iruses.
omologous titers are indicated in bold and underlined.thermore, variability of H3N2 inﬂuenza virus isolation rates in eggs
in recent years [22,23] can add additional risk of the introduction
of egg-adaptive changes that have an impact on the antigenicity
of the vaccine virus within the current system. Therefore, the use
of CVVs isolated or synthetically generated in certiﬁed mammalian
cells could help increase the number of viruses available for CVV
selection and, in some circumstances, provide viruses for vaccine
manufacture that better correspond antigenically to the circulating
strains.
MDCK cells have both -2,6- and -2,3-linked sialic acids
on their surfaces, making them a more neutral substrate with
respect to selection of altered variants of inﬂuenza virus [11].
Sequence analysis of inﬂuenza viruses in clinical samples and
their laboratory-passaged derivatives have conﬁrmed that MDCK
rived B antigens.
history Post-Infection ferret antisera
B/Brisbane/60/08-egg B/Brisbane/60/08-cell
F30/10 NIBSC66/10
3) 640 160
CKx/MDCK4) 20 160
CK1) 640 160
CK3) 40 160
story of the viruses that provided the HA and NA sequences to make the synthetic
P. Suphaphiphat et al. / Vaccine 34 (2016) 3641–3648 3647
Table  5
Two-way HI test for the H3N2 strain A/Switzerland/9715293/2013.
Antigen
sourcea
Passage
history
Post-Infection ferret antiserab
A/Switz/9715293 A/Switz/9715293 A/Switz/9715293 A/Switz/9715293
(WT) egg (WT) cell (S) egg RG-PS-2404 (S) cell RG-ID-1985
NIBSC F29/15 NIBSC F13/14 F40/14 F439/14
Reference viruses
A/Switzerland/9715293/2013-egg Egg E4/E1
clone 123
640 160 1280 160
A/Switzerland/9715293/2013-cell Cell SIAT1/SIAT3 80 320 320 320
Test  viruses
RG-PS-2404 (A/Switzerland/9715293/2013-egg) PR8x Egg MDCK1 320 160 640 160
RG-PS-2411 (A/Switzerland/9715293/2013-egg) #21 Egg MDCK1 320 160 640 160
RG-PS-2407 (A/Switzerland/9715293/2013-cell) PR8x Cell MDCK1 160 320 320 320
RG-ID-1985 (A/Switzerland/9715293/2013-cell) #21 Cell MDCK1 160 640 640 640
RG-PS-2400 (A/Switzerland/9715293/2013-cell) #19 Cell MDCK1 160 320 320 320
a “Egg” or “cell” refers to the passage history of the reference viruses or the passage history of the viruses that provided the HA and NA sequences to make the synthetic
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to generate, titer, and sequence synthetic viruses; RD provided sci-iruses.
b Post-infection ferret antisera was raised to either wild-type isolates (WT) or syn
omologous titers are indicated in bold and underlined.
ells are more likely than chicken eggs to maintain the prevalent
A genotypes present in clinical material [16]. MDCK cell-grown
iruses are also more antigenically similar to the viruses replicat-
ng in humans than their egg-grown counterparts, as evidenced
y their greater recognition by neutralizing and HI antibodies in
ost-infection human sera [24,25].
To that end, we have established a synthetic system for gener-
ting CVVs exclusively in MDCK cells from sequence information
18]. This system has the potential to improve antigenic similar-
ty to strains that cause human disease. For each new inﬂuenza A
irus, a set of high-growth backbones can be tested empirically to
dentify the highest-yielding option for that particular HA and NA
n mammalian cells and eggs. The backbones that we  have estab-
ished for inﬂuenza A viruses can increase virus rescue efﬁciency in
DCK cells and HA yields in both MDCK cells and in eggs [18]. This
ynthetic technology, combined with a standard PR8 backbone, has
lready been used to produce an H7N9 vaccine candidate that had
 good safety proﬁle and elicited antibody titers considered protec-
ive in a phase I trial [26]. Demonstrating that alternative backbones
o not interfere with the antigenic properties of synthetic vaccine
iruses would help facilitate the use of higher yielding chimeric
ackbones to produce CVVs for human vaccines.
In this study, we have shown that synthetic viruses could be
roduced that antigenically correspond to either egg- or mam-
alian cell-propagated isolates, based solely on the HA and NA
equences chosen for gene synthesis. Seasonal viruses generated
ith synthetic DNA and alternative backbones were passaged up
o three times in a vaccine-approved MDCK cell line, and antigenic
tability was established by HI titers comparable to those of the cor-
esponding conventional reference strains. Although it is plausible
hat differences in the internal genes could affect certain physical
roperties of the virion, such as morphology or HA incorporation,
hich could in turn affect the dynamics of the HI assay, we have
onﬁrmed that the different backbones had no signiﬁcant effect on
ntigenic characterization of the viruses. This ﬁnding was  not unex-
ected since antigenicity should merely reﬂect the HA that has been
ntroduced into the synthetic virus.
Although viruses passaged in MDCK cells generally do not
cquire adaptive mutations in HA, some H3N2 viruses (which may
ave HA molecules with low afﬁnity for cell surface sialic acid)
ave been reported to acquire upon passage a mutation in the NA
ialic acid binding site that facilitates binding to MDCK cells [27].
lthough the selected NA mutation does not interfere with the anti-
enic and immunogenic properties of the mutated viruses, per se,
he altered properties of NA result in NA-mediated hemagglutina-
ion and consequent changes to HI titers. To block this NA-mediatedc viruses (S)
hemagglutination, the NA inhibitor oseltamivir was added to the HI
assays for all H3N2 strains in the studies we  are reporting.
The ability of synthetic seed technology to increase the num-
ber of strains with new HAs and NAs that can be isolated and
to provide strains that are more similar to a mammalian cell-
grown prototype virus may  improve antigenic similarity between
the vaccine and viruses circulating in humans. In addition, the
ability to generate CVVs rapidly using this technology compared
to egg-based reassortment [18] could potentially allow strain
recommendations to be made later, thus reducing the lag time
between strain selection and vaccine distribution, during which
antigenic drift may  occur. The relative clinical effectiveness of vac-
cines that better corresponds to viruses in circulation still needs
to be determined. Although antigenic characterization by HI pro-
vides important information about whether a vaccine made using
the vaccine virus will protect against circulating strains, there
are some limitations to using this methodology as a surrogate
for immunogenicity or vaccine effectiveness. In particular, post-
infection antisera raised against egg- and cell-derived vaccine
viruses in immunologically naïve ferrets may  not necessarily reﬂect
the antibody repertoire elicited by inactivated and split vaccines
in humans with pre-existing immunity. Nevertheless, the exclu-
sive use of mammalian cells for generating CVVs and for antigen
manufacture could reduce the potential risks associated with egg-
adaptive mutations in inﬂuenza vaccine antigens.
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